• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

April 3, 2015

View Archived Issues

In the clinic

Clementia Pharmaceuticals Inc., of Montreal, said the data monitoring committee for the company's phase II adaptive-design, dose-ranging study of palovarotene for fibrodysplasia ossificans progressiva has completed a planned review of efficacy and safety data from the first cohort of patients in the study. Read More

Appointments and advancements

Chiasma Inc., of Newton, Mass., and Jerusalem, appointed Mark Leuchtenberger president and CEO. Read More

Other news to note

Gtx Inc., a Memphis, Tenn.-based company that has seen its shares (NASDAQ:GTXI) struggle ever since sharing disappointing results from a phase III study of enobosarm for muscle wasting in non-small-cell lung cancer patients in 2013, said it plans to meet the $1 minimum bid price requirement for continued listing on Nasdaq by effecting a reverse stock split, if necessary. Read More

Stock movers

Read More

Financings

Corcept Therapeutics Inc., of Menlo Park, Calif., said it issued warrants to accredited investors in two private placements, one that was completed in March 2008 and the other in March 2012. Read More

Perosphere lands fast track status for its anticoagulant reversal agent PER977

Perosphere Inc., a private company focused on bringing a broadly applicable anticoagulant reversal agent to market, has won FDA fast track status for the synthetic small molecule ahead of planned phase III studies. Read More

Novel cancer genomics approach brings melanoma vaccine

Researchers have reported early data from a clinical trial that used a combination of genomics and immunotherapy to develop personalized dendritic cell vaccines for patients with metastatic melanoma. Read More

Pfizer halting China vaccines sales, awaiting Prevnar 13 import license

HONG KONG – In another blow to the operations of multinational pharmaceutical companies in China, Pfizer Inc. may have to suspend its vaccine business temporarily as it shifts from Prevenar 7 to Prevenar 13. Read More

Please advise: NDA's in, Repros hopes for panel that could be 'landmark'

The latest chapter in the long saga of Repros Therapeutics Inc.'s quest to get an estrogen blocker approved for secondary hypogonadism in overweight men gave investors cause for both optimism and concern, as the FDA's acceptance for filing of the new drug application (NDA) brought questions about the timing of an advisory committee meeting – and what U.S. gatekeepers might want next. Read More

Pharma: Other news to note

Johnson & Johnson Innovation-JJDC Inc., of New Brunswick, N.J., made a $15 million commitment to Vivo Capital Fund VIII, an investment firm focusing on health care companies in the U.S. and China. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe